Ser463
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser463  -  RIMS2 (human)

Site Information
AQRTTNHsPPtPRRs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 481531
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:
breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 ) , non-small cell lung cancer ( 4 , 5 , 6 ) , non-small cell lung adenocarcinoma ( 4 , 5 , 6 ) , non-small cell large cell lung carcinoma ( 4 , 5 ) , small-cell lung cancer ( 2 , 3 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , DMS153 (pulmonary) ( 6 ) , DMS53 (pulmonary) ( 3 ) , DMS79 (pulmonary) ( 2 ) , HCC78 (pulmonary) ( 5 ) , lung ( 2 , 3 , 4 , 5 , 6 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 6 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 6 ) , NCI-H209 (pulmonary) ( 2 , 6 ) , NCI-H2228 (pulmonary) ( 5 ) , NCI-H3122 (pulmonary) ( 5 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H446 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H524 (pulmonary) ( 2 ) , NCI-H526 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 5 ) , NCI-H69 (pulmonary) ( 3 ) , NCI-H82 (pulmonary) ( 3 ) , NCI-H838 (pulmonary) ( 6 )

References 

1

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info